[{"id":"c004ade3-4442-4c21-9ed1-2d8593e8f714","acronym":"QPT-ORE-004","url":"https://clinicaltrials.gov/study/NCT05335993","created_at":"2022-04-20T16:53:39.435Z","updated_at":"2024-07-02T16:35:23.399Z","phase":"Phase 2","brief_title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","source_id_and_acronym":"NCT05335993 - QPT-ORE-004","lead_sponsor":"CanariaBio Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • OvaRex (oregovomab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-15"},{"id":"a5e6c6d0-a78e-4f58-8fa1-e6a7380f2863","acronym":"FLORA-5","url":"https://clinicaltrials.gov/study/NCT04498117","created_at":"2023-12-04T19:35:02.068Z","updated_at":"2024-07-02T16:35:26.036Z","phase":"Phase 3","brief_title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","source_id_and_acronym":"NCT04498117 - FLORA-5","lead_sponsor":"CanariaBio Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • OvaRex (oregovomab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 615","initiation":"Initiation: 08/25/2020","start_date":" 08/25/2020","primary_txt":" Primary completion: 09/26/2025","primary_completion_date":" 09/26/2025","study_txt":" Completion: 08/26/2027","study_completion_date":" 08/26/2027","last_update_posted":"2023-12-18"},{"id":"9df4be6b-ff41-4f1f-9f7e-3112f887c2b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04938583","created_at":"2021-06-24T16:53:00.541Z","updated_at":"2024-07-02T16:35:33.045Z","phase":"Phase 1b/2","brief_title":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04938583","lead_sponsor":"CanariaBio Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • OvaRex (oregovomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-10-17"},{"id":"c580b30f-ac45-400c-9775-3285acd7fff5","acronym":"ORION-02","url":"https://clinicaltrials.gov/study/NCT04620954","created_at":"2021-01-19T20:34:28.547Z","updated_at":"2025-02-25T14:29:42.529Z","phase":"Phase 1/2","brief_title":"Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin","source_id_and_acronym":"NCT04620954 - ORION-02","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • OvaRex (oregovomab) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2021-12-01"},{"id":"fb7670d2-fea2-4ef0-baff-61466bba16a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00551265","created_at":"2021-01-18T02:00:28.201Z","updated_at":"2024-07-02T16:37:19.887Z","phase":"","brief_title":"Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy","source_id_and_acronym":"NCT00551265","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • OvaRex (oregovomab) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2007","start_date":" 10/01/2007","primary_txt":" Primary completion: 01/01/2009","primary_completion_date":" 01/01/2009","study_txt":"","study_completion_date":"","last_update_posted":"2017-07-14"}]